GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (STU:2RH0) » Definitions » Additional Paid-In Capital

Redhill Biopharma (STU:2RH0) Additional Paid-In Capital : €351.53 Mil(As of Jun. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Redhill Biopharma Additional Paid-In Capital?


Redhill Biopharma's quarterly additional paid-in capital declined from Dec. 2022 (€361.20 Mil) to Mar. 2023 (€357.38 Mil) but then stayed the same from Mar. 2023 (€357.38 Mil) to Jun. 2023 (€351.53 Mil).

Redhill Biopharma's annual additional paid-in capital increased from Dec. 2021 (€332.09 Mil) to Dec. 2022 (€361.20 Mil) but then declined from Dec. 2022 (€361.20 Mil) to Dec. 2023 (€356.13 Mil).

Redhill Biopharma Additional Paid-In Capital Historical Data

The historical data trend for Redhill Biopharma's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Additional Paid-In Capital Chart

Redhill Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 240.66 240.96 332.09 361.20 356.13

Redhill Biopharma Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Dec23
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 387.24 361.20 357.38 351.53 356.13

Redhill Biopharma Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Redhill Biopharma Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Redhill Biopharma (STU:2RH0) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (STU:2RH0) » Definitions » Additional Paid-In Capital
Comparable Companies
CLSH PLSH CNNC YCBD PTPI HENC KOAN STEK CLVR JUVAF ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692
Traded in Other Exchanges
RDHL:USA 2RH0:Germany
Address
21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
Website
https://www.redhillbio.com
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.

Redhill Biopharma (STU:2RH0) Headlines

No Headlines